Moody’s changes Eli Lilly view

Moody's Ratings said it affirmed the ratings of Eli Lilly and Co. including the A1 senior unsecured notes and issuer rating.

The agency also affirmed the provisional A1 senior unsecured medium-term note program and the Prime-1 short-term rating.

Moody's revised the outlook to positive from stable.

“The outlook change to positive reflects Eli Lilly's leading position in diabetes and obesity care, illustrated by very strong growth prospects from incretins including Zepbound and Mounjaro,” Michael Weinstein, Moody's vice president, senior analyst, said in a news release.

“If Zepbound is eventually approved for label expansion in additional indications such as sleep apnea, growth prospects could further expand.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.